News & Analysis on Clinical Trial Services & Contract Research And Development
Hired and (not) retired: Major moves at the top of Merck, Pfizer and Bayer
By Maggie Lynch
- Last updated on
The two major pieces of news involved two countdowns: Merck, known as MSD in Europe, revealed what decision it would make on its CEO, as Ken Frazier approached 65 and the company's mandatory retirement policy suggested that he would have to step down as a result.
Pfizer had already taken this action with its CEO, Ian Reed, but now he has announced that he will step down from his position by January 2019 and has given his blessing to a successor.